Imperva Announces Fourth Quarter and Full Year 2015 Financial Results

Go back to Imperva Announces Fourth Quarter and Full Year 2015 Financial Results

Needham & Company Reiterates Buy Following Imperva's (IMPV) 4Q Beat and Raise

February 4, 2016 6:45 AM EST

Needham & Company maintained a Buy rating on Imperva (NYSE: IMPV), and cut the price target to $56.00 (from $88.00), following the company's 4Q earnings report. IMPVs $72.7m and $0.20 was comfortably above $68.1m and $0.15 EPS consensus, yet investor expectations were high going into earnings. CY16 old guidance was for $285m, and last night IMPV revised... More

Imperva (IMPV) Tops Q4 EPS by 5c, Q1 & FY16 Guidance Falls Short

February 3, 2016 4:17 PM EST

Imperva (NYSE: IMPV) reported Q4 EPS of $0.20, $0.05 better than the analyst estimate of $0.15. Revenue for the quarter came in at $72.7 million versus the consensus estimate of $68.16 million.

GUIDANCE:

Imperva sees Q1 2016 EPS of ($0.26)-($0.32), versus the consensus of ($0.12). Imperva sees... More